Prokidney Corp Banner Image

Prokidney Corp

  • Ticker PROK
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Prokidney Corp Logo Image
  • 51-200 Employees
  • Based in Winston-Salem, North Carolina
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in someMore cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
Prokidney Corp

Most Recent Annual Report

Prokidney Corp
MOST RECENT 2022 Annual Report and Form 10K
Prokidney Corp Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!